Comprehensive Analysis of Exosome Gene LYPD3 and Prognosis/immune Cell Infiltration in Lung Cancer

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Apr 15

PMID 38617517

Authors

Tao Xin

Chunlong Zheng

Gui-Zhen Li

Xinyao Xu

Jipeng Zhang

Chenghui Jia

Pengyu Jing

Qiang Lu

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer (LC) is a leading cause of cancer-associated mortality worldwide, with high incidence and mortality rates. Ly6/PLAUR domain containing 3 (LYPD3) is a tumorigenic and highly glycosylated cell surface protein that has been rarely reported in LC. This study aimed to explore the prognostic role and immune cell infiltration of LYPD3 in LC.

Methods: We used ExoCarta, a database of exosomal proteins and RNA, to select exosomes in LC. The Tumor Immune Estimation Resource (TIMER) and Human Protein Atlas (HPA) databases were utilized to compare the expression of LYPD3 in LC. We applied Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and Kaplan-Meier (KM) plotter to evaluate the prognostic prediction performance of LYPD3. Biological processes (BPs), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, and gene set enrichment analysis (GSEA) analyses were performed to illustrate the possible role of LYPD3 in LC. The correlations between LYPD3 and immune cell infiltration were explored using Tumor and Immune System Interaction Database (TISIDB), GEPIA2, and TIMER. R software was used for statistical analysis and mapping.

Results: A total of 904 exosome molecules were screened in LC. Further analysis showed that the up-regulation of LYPD3 in these 904 exosome molecules was associated with poor prognosis in LC. Pan-cancer analyses revealed that the expression of LYPD3 varied in many cancers, particularly in LC. Clinical correlation analysis indicated that LYPD3 was associated with stage and T classification in LC. We observed that LYPD3 co-expression genes were associated with cell cycle, DNA replication, proteasome, and regulation of the actin cytoskeleton by GSEA. Moreover, LYPD3 was associated with immune modulators. Immunophenoscores (IPS) and IPS-CTLA4 were significantly different between the high LYPD3 group and low LYPD3 group. Additionally, the median half maximal inhibitory concentration (IC) of bexarotene, cyclopamine, etoposide, and paclitaxel in LYPD3 high group was significantly lower than that in LYPD3 low group.

Conclusions: LYPD3 is involved in many BPs of LC, such as regulating immune cell infiltration and affecting prognosis. Therefore, LYPD3 may have potential value as a biomarker for prognosis and immunotherapy in LC.

Citing Articles

Advancements and trends in exosome research in lung cancer from a bibliometric analysis (2004-2023).

Zhong W, Zhao X, Zhang X, Xu Y, Liu M, Yang X Front Oncol. 2024; 14:1358101.

PMID: 38690166 PMC: 11058220. DOI: 10.3389/fonc.2024.1358101.

References

Klempner S, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali S . Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist. 2019; 25(1):e147-e159. PMC: 6964127. DOI: 10.1634/theoncologist.2019-0244. View

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

Rosel M, Claas C, Seiter S, Herlevsen M, Zoller M . Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor. Oncogene. 1998; 17(15):1989-2002. DOI: 10.1038/sj.onc.1202079. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Gruet M, Cotton D, Coveney C, Boocock D, Wagner S, Komorowski L . β2-Adrenergic Signalling Promotes Cell Migration by Upregulating Expression of the Metastasis-Associated Molecule LYPD3. Biology (Basel). 2020; 9(2). PMC: 7168268. DOI: 10.3390/biology9020039. View

Shimizu K, Iyoda T, Okada M, Yamasaki S, Fujii S . Immune suppression and reversal of the suppressive tumor microenvironment. Int Immunol. 2018; 30(10):445-454. DOI: 10.1093/intimm/dxy042. View

Walia A, Tuia J, Prasad V . Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed. Nat Rev Clin Oncol. 2023; 20(12):885-895. DOI: 10.1038/s41571-023-00823-5. View

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D . Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):248-262. DOI: 10.1016/j.celrep.2016.12.019. View

Zhao F, Tian H, Liu X, Guan Y, Zhu Y, Ren P . Homeobox A1 Facilitates Immune Escape and Alleviates Oxidative Stress in Lung Adenocarcinoma. Oxid Med Cell Longev. 2022; 2022:4102666. PMC: 9136634. DOI: 10.1155/2022/4102666. View

10.

Duma N, Santana-Davila R, Molina J . Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019; 94(8):1623-1640. DOI: 10.1016/j.mayocp.2019.01.013. View

11.

Del Rivero J, Enewold L, Thomas A . Metastatic lung cancer in the age of targeted therapy: improving long-term survival. Transl Lung Cancer Res. 2017; 5(6):727-730. PMC: 5233873. DOI: 10.21037/tlcr.2016.11.08. View

12.

Upadhyay G . Emerging Role of Lymphocyte Antigen-6 Family of Genes in Cancer and Immune Cells. Front Immunol. 2019; 10:819. PMC: 6491625. DOI: 10.3389/fimmu.2019.00819. View

13.

Hu P, Huang Y, Gao Y, Yan H, Li X, Zhang J . Elevated Expression of Is Associated with Lung Adenocarcinoma Carcinogenesis and Poor Prognosis. DNA Cell Biol. 2020; 39(4):522-532. DOI: 10.1089/dna.2019.5116. View

14.

Sorber L, Zwaenepoel K, Deschoolmeester V, Van Schil P, Van Meerbeeck J, Lardon F . Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer. 2016; 107:100-107. DOI: 10.1016/j.lungcan.2016.04.026. View

15.

Zhang L, Yu D . Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. 2019; 1871(2):455-468. PMC: 6542596. DOI: 10.1016/j.bbcan.2019.04.004. View

16.

Andus I, Prall F, Linnebacher M, Linnebacher C . Establishment, characterization, and drug screening of low-passage patient individual non-small cell lung cancer models including the rare pleomorphic subentity. Front Oncol. 2023; 13:1089681. PMC: 10203569. DOI: 10.3389/fonc.2023.1089681. View

17.

Jardim D, Goodman A, Gagliato D, Kurzrock R . The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2020; 39(2):154-173. PMC: 7878292. DOI: 10.1016/j.ccell.2020.10.001. View

18.

Clausen M, Langer S . Improving the prognosis for lung cancer patients. Acta Oncol. 2019; 58(8):1077-1078. DOI: 10.1080/0284186X.2019.1632477. View

19.

Willuda J, Linden L, Lerchen H, Kopitz C, Stelte-Ludwig B, Pena C . Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer. Mol Cancer Ther. 2017; 16(5):893-904. DOI: 10.1158/1535-7163.MCT-16-0474. View

20.

van Putten J, Strijbis K . Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer. J Innate Immun. 2017; 9(3):281-299. PMC: 5516414. DOI: 10.1159/000453594. View